Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.
Articles
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.
Why Is The Psychedelic Drug Industry Suddenly In Favor With Global Power Players?
The psychedelic drug industry has suddenly attracted the attention of the most influential "power players" on the planet. It's great news for the industry, but...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.
MindMed Appoints Schond L. Greenway as Chief Financial Officer
MindMed announces the appointment of Schond L. Greenway as its new CFO, bringing a wealth of experience in banking and corporate finance.
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
GH Research reports its Q1 2022 results. Net loss of $5.8 million. Cash position of $270.8 million as of March 31, 2022.
Mydecine Announces Size of Previously Announced Overnight Marketed Public Offering of Units
Mydecine Innovations Group announces the issuance of 3,478,260 units at a unit price of CAD$1.15, for gross proceeds of up to CAD$4 million.
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
Seelos Therapeutics announces receiving its Notice of Allowance from the USPTO for SLS-007 as a method of treatment.
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
Awakn Life Sciences announce promising results from the first study of ketamine-assisted therapy for behavioral addictions, and will be initiating a larger follow-up study.
U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening
Optimi Health announces that UK MP, Cristin Blunt will be appearing as a guest speaker at the grand opening ceremony for its Princeton, B.C. cultivation facility.
Novamind Launches Group Psychedelic Treatment for Frontline Workers
Novamind announces the full-scale launch of Frontline KAP, group-based ketamine-assisted therapy for frontline healthcare workers suffering from burnout/stress/trauma, at select clinic locations.
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
MindMed announces positive safety and tolerability results from its Phase 1 clinical trial of MM-110 (18-MC) as a treatment for opioid withdrawal.
Albert Labs Granted Health Canada Licence
Albert Labs announces the receipt of its Dealer's License from Health Canada, allowing possession/sale/delivery of psilocybin and other controlled substances.
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics
Optimi Health announces the acquisition of a diverse catalogue of psilocybin and functional mushroom strains intended for cultivation.
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.